Inhibrx Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 172
- Market Cap
- $205.4M
- Website
- http://inhibrx.com
Clinical Trials
13
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Interventions
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Inhibrx Biosciences, Inc
- Target Recruit Count
- 410
- Registration Number
- NCT06295731
- Locations
- 🇧🇪
Antwerp University Hospital, Edegem, Antwerp, Belgium
🇧🇬Multiprofile Hospital for Active Treatment - "Uni Hospital" Ltd, Medical Oncology Dept, Panagyurishte, Bulgaria
🇧🇬Complex Oncological Center Plovdiv EOOD Dept of Med Oncology and Oncological Diseases in Hematology, Plovdiv, Bulgaria
Study of INBRX-109 in Conventional Chondrosarcoma
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Inhibrx Biosciences, Inc
- Target Recruit Count
- 201
- Registration Number
- NCT04950075
- Locations
- 🇺🇸
Precision NextGen Oncology & Research Center, Beverly Hills, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸University of Oklahoma - Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Conditions
- Solid TumorRenal Cell CarcinomaHead and Neck CancerUrothelial CarcinomaMelanomaNon-Small Cell Lung CancerGastric Cancer
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Inhibrx Biosciences, Inc
- Target Recruit Count
- 333
- Registration Number
- NCT04198766
- Locations
- 🇺🇸
Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸City of Hope, Duarte, California, United States
Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency
- Conditions
- Alpha-1 Antitrypsin DeficiencyAATD
- Interventions
- Drug: INBRX-101/rhAAT-Fc
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- Inhibrx Biosciences, Inc
- Target Recruit Count
- 31
- Registration Number
- NCT03815396
- Locations
- 🇺🇸
UC Davis School of Medicine, Sacramento, California, United States
🇺🇸University of Florida College of Medicine, Gainesville, Florida, United States
🇺🇸University of Miami, Miami, Florida, United States
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
- Conditions
- Head and Neck Squamous Cell CarcinomaNon-small Cell Lung CancerMelanomaGastric AdenocarcinomaMetastatic Solid TumorsRenal Cell CarcinomaNasopharyngeal CarcinomaEsophageal AdenocarcinomaOropharyngeal Carcinoma
- Interventions
- Drug: INBRX-105 - PDL1x41BB antibody
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Inhibrx Biosciences, Inc
- Target Recruit Count
- 160
- Registration Number
- NCT03809624
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸City of Hope at Irvine Lennar, Duarte, California, United States
🇺🇸City of Hope, Duarte, California, United States
- Prev
- 1
- 2
- Next
News
Inhibrx's Ozekibart Shows Promise in Phase 1 Colorectal Cancer Trial
Inhibrx Biosciences announced preliminary Phase 1 data for ozekibart (INBRX-109) combined with FOLFIRI in advanced colorectal adenocarcinoma, presented at ASCO GI Cancers Symposium.